A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
Clinical trial NCT00423202 · COMPLETED
Trial details
- NCT number
- NCT00423202
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2003-12-01
- Enrollment
- 186
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.